Compare MOLN & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MOLN | FLC |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Trusts Except Educational Religious and Charitable |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.5M | 172.4M |
| IPO Year | 2021 | 2003 |
| Metric | MOLN | FLC |
|---|---|---|
| Price | $3.99 | $16.12 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.38 | N/A |
| AVG Volume (30 Days) | 1.6K | ★ 27.8K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $374.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $15.89 |
| 52 Week High | $5.36 | $18.09 |
| Indicator | MOLN | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 32.22 |
| Support Level | $3.78 | $15.89 |
| Resistance Level | $4.35 | $17.00 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 17.05 | 25.42 |
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.